China Energy Storage Technology Development Limited — Board/Management Information 2021

Jan 6, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [61 x 32] intentionally omitted <==

==> picture [61 x 32] intentionally omitted <==

Link-Asia International Co. Ltd. 環亞國際實業有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR (2) CHANGE OF COMPOSITION OF BOARD COMMITTEES AND (3) COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

The board (the ‘‘Board’’) of directors (the ‘‘Directors’’) of Link-Asia International Co. Ltd (the ‘‘Company’’) hereby announces the following changes in the Company:

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Sun Xiaohu (‘‘Dr. Sun’’) has been appointed as an independent non-executive Director and a member of audit committee of the Company (the ‘‘Audit Committee’’) with effect from 6 January 2021.

The biographical details of Dr. Sun are set out below:

Dr. Sun, aged 56, holds a doctoral degree of medicine (immunology) from Shanghai Jiao Tong University School of Medicine and a certificate of EMBA (核 心 課程 總 裁高級 研修班 ) issued by Center for National Strategic Studies, Shanghai Jiao Tong University (上海交 通 大 學國家戰略 研 究中 心 ). Dr. Sun has more than 30 years’ experience in biotechnology companies, pharmaceutical companies, medical enterprises, research institutes and hospitals; and nearly 20 years’ experience as senior management in domestic and international pharmaceutical and medical device companies. From 10 October 2018 to 31 March 2020, Dr. Sun was the chief operating officer of China Regenerative Medicine International Limited, a company whose shares are listed on GEM board of the Stock Exchange of Hong Kong (Stock Code: 08158). He also held various positions with companies in the PRC including the operation director and marketing director of Vcanbio Cell & Gene Engineering Corp., Ltd. (中 源 協和細胞基因 工 程股份有限公司) whose shares are listed on Shanghai Stock Exchange (Stock Code: 600645); the general manager of Shanghai Claison Bio-tech Co., Ltd. (上海柯萊 遜 生 物 技術有限公司), the general manager of Shanghai Dongha Pharmaceutical Co., Ltd. (上海東海製藥股份有限公司); the marketing director of Heho Biotech (Shanghai) Co., Ltd. under Morningside Group (晨興集團和 泓 生 物 技術(上海)有限 公司); the assistant group general manager of Vitop Bioenergy (China) Limited. (天年生

– 1 –

物 (中國)有限公司); general manager of its Shanghai company; the director of East China office of Tat Lung Medical Treatment Technology Limited; the vice president of marketing of Shenzhen Biological Valley Technology Investment Co., Ltd. (深圳市生 物 穀科技投 資 有 限公司) and the administrative physician/assistant to department director of Qingdao University Medical College.

Dr. Sun will enter into an appointment letter as an independent non-executive Director with the Company for an initial term of three years, and will be subject to retirement by rotation and re-election at general meeting of the Company in accordance with the Company’s articles of association. Dr. Sun is entitled to a directors’ fee of HK$360,000 per annum as specified in his letter of appointment, which is determined by the Board (the decision of which was based on the recommendation of the remuneration committee of the Company (the ‘‘Remuneration Committee’’)) with reference to his duties and responsibilities in the Company, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, as at the date of this announcement, Dr. Sun: (i) does not hold any other positions with the Company or other members of the Group; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company; (iii) has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Saved as disclosed above, there is no other information to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to subparagraphs (h) to (v) therein) nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to the appointment of Dr. Sun.

The Board would like to take this opportunity to welcome Dr. Sun on joining the Board.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following the appointment of Dr. Sun, he will be the member of the Audit Committee with effect from 6 January 2021.

COMPLIANCE WITH REQUIREMENTS UNDER RULES 3.10 AND 3.21 OF THE LISTING RULES

According to Rule 3.10(1) of the Listing Rules, the Company is required to have at least three independent non-executive Directors. According to Rule 3.21 of the Listing Rules, the Audit Committee must comprise a minimum of three members, and comprise non-executive Directors only.

– 2 –

Following the appointment of Dr. Sun,

• (1) the Company has three independent non-executive Directors, thus the number of independent non-executive Directors meets the minimum number required under Rule 3.10(1) of the Listing Rules; and

• (2) the Audit Committee has three members and all members are non-executive Directors, thus meets the requirement under Rule 3.21 of the Listing Rules.

By order of the Board Link-Asia International Co. Ltd. Lin Dailian Chairman and executive Director

Hong Kong, 6 January 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Dr. Sun Xiaohu as independent non-executive Directors.

– 3 –